In brief. To recruit a medtech CEO, one must first define the mission they are being called to: turning around governance, relaunching strategy following a vacancy, leading a PE-backed company through to its exit, or integrating an enterprise into a corporate group. Each mission calls for a different profile. In three high-profile public cases from 2025 and 2026 (Hologic, Masimo, Coloplast), leadership changes coincided, in two out of three instances, with the closing of a capital transaction.

In early April 2026, Blackstone and TPG finalized the buyout of Hologic, an American specialist in women's health devices, for an amount that could reach $18.3B. At the same time, the company announced on April 7 that José Almeida, former Chairman and CEO of Baxter, would take the helm effective immediately. Stephen MacMillan, at the head of Hologic for more than twelve years, stepped down.

On June 10, 2026, Danaher finalized the acquisition of Masimo for $9.9B. Roughly four days later, Masimo's Chief Executive Officer, Katie Szyman, appointed in February 2025, announced her departure and transitioned to an advisory role at Danaher for the integration.

Meanwhile, in Denmark, Coloplast waited nearly twelve months: its CEO stepped down on May 5, 2025, the Chairman of the Board served as interim CEO, and the name of the successor, Gavin Wood, was only announced on March 4, 2026, ahead of taking office on May 1.

These three stories share neither the same shareholding structure, nor the same geography, nor the same timeline. Yet they pose the exact same question to any board and any private equity fund: what specific mission is the next executive being called to fulfill?

Key figures to know

Why this issue matters right now

Three executive leadership transitions across medical devices over a thirteen-month period, from May 2025 to June 2026, can now be analyzed across their full durations. Two of them coincide with a major capital transaction. The third illustrates what a succession costs, in terms of time, in the absence of a transaction.

The European regulatory framework adds another layer of uncertainty. The European Commission's proposal on revising the MDR and IVDR dates from late 2025, with adoption targeted around mid-2027, according to Emergo by UL. In the meantime, the current rules remain fully applicable. The Panorama France HealthTech 2026 report emphasizes that MDR-related delays are lengthening and hampering market access. A medtech CEO must navigate this timeline without being able to control it.

Three common misconceptions circulate widely.

A medtech CEO must come from an engineering or clinical background. While that can be valuable, it misses the point. The real question is whether the executive has already navigated the specific phase targeted.

A veteran from a large corporate group is always sufficient. A corporate executive is accustomed to having resources that an emerging or mid-sized medtech simply will not have. Boards must look at what a candidate has delivered with limited resources, not what they have overseen with abundance.

The transaction CEO is the holding period CEO. Closing a buyout changes the mandate entirely: the leader who orchestrated the sale is rarely the one best suited to steer the company through the years that follow.

One mission, four playbooks

This analysis represents our perspective: official announcements highlight career backgrounds and dates, not the closed-door deliberations of boards. It assumes that an appointment reflects the explicit mandate shareholders intend to deliver on.

The story behind Coloplast's 361 days

On May 5, 2025, Coloplast announced that its CEO, Kristian Villumsen, was stepping down. Lars Rasmussen, then Chairman of the Board, stepped in as interim CEO, relinquishing his chairmanship. Jette Nygaard-Andersen became interim Chair. The Board indicated that it was launching an executive search to lead the company into a new strategic chapter.

On March 4, 2026, Coloplast announced the appointment of Gavin Wood, a Swiss-based Canadian executive with twenty years at Johnson & Johnson, most recently heading the MedTech business across Europe, the Middle East, and Africa with over 7,000 employees, and previously leading wound care and closure at Ethicon and serving as Chief Commercial Officer at Mölnlycke. He also serves as Vice-Chair of MedTech Europe. He stepped into the role on May 1, 2026. Between departure and onboarding: 361 days.

We do not know the internal factors that made this timeline take so long, nor will we speculate. What can be clearly analyzed, however, is what such an extended transition demands of a board.

A lengthy interim is its own governance regime. The former Chairman serving as interim CEO, the interim Chair of the Board, and the search committee together form a framework where operational and oversight responsibilities must be formalized in writing.

The selected profile articulates the mandate. An executive who understands surgery, wound management, European distribution networks, and pan-European industry representation directly matches a mandate centered on European commercial relaunch.

Onboarding followed the announcement swiftly. Between the public announcement and start date, only 58 days elapsed: a rapid turnaround compared to the ten preceding months.

The deal CEO is rarely the holding-period CEO

The Hologic and Masimo transactions highlight a pivot that shareholders rarely plan for sufficiently: the deal closing.

Upon the closing of Hologic's buyout by Blackstone and TPG, incumbent chief executive Stephen MacMillan stepped down after more than twelve years, and the Board immediately appointed an executive who had already led two major global medical device corporations. At Masimo, the CEO announced her departure around four days post-closing, staying on as an advisor to the buyer during integration. Masimo subsequently announced in August the appointment of a new president promoted from commercial leadership.

In both situations, the executive leadership transition matched a fundamental transformation in the nature of the organization. Ahead of closing, the company required a leader suited to execute a corporate deal. After closing, it needed an executive built to deliver on a fundamentally distinct operational mission.

AlixPartners' annual survey of 427 PE executives, published on March 25, 2026, provides a clear benchmark for what buyout funds experience. 65% of PE firms report having replaced a CEO during the holding period, and 83% of fund leaders state that an unplanned leadership change extends the hold duration. While these figures encompass all industries rather than healthcare alone, they reflect widespread market practice rather than isolated exceptions.

For an investment fund that holds or is acquiring a medtech company, the takeaway is pragmatic: the holding-period CEO must be determined prior to deal signing, with a written roadmap, quantifiable success metrics, and an anticipated exit target.

Regulation and fundraising: two imperatives a CEO cannot delegate

In the medtech industry, regulatory compliance is not merely one administrative matter among many. It establishes the rhythm of product commercialization, and thus the cadence of funding requirements.

The Panorama France HealthTech 2026 survey observes that 53% of medtech and diagnostic products are currently in registration or commercialization phases (compared with 49% in 2024), with 28% holding a CE mark (vs. 24%). It notes, furthermore, that MDR-related timelines continue to stretch out and that a majority of businesses are lobbying for expedited access pathways, with 46% demanding stricter oversight over review costs and agency response times. In France, 52% of HealthTech ventures view an acquisition/trade sale as their preferred exit strategy.

This reality establishes three inescapable imperatives for the executive leadership.

1. Master the regulatory roadmap: Be able to communicate to the board, product by product, when the company can achieve commercial launch and under what regulatory constraints.

2. Manage extended funding cycles: Fundraising takes an average of ten months in the French HealthTech space, according to the same survey.

3. Ensure the business is transaction-ready: A medtech company planning an eventual sale must meticulously substantiate its gross margins, certification dossiers, and distributor dependency risks.

When leadership stems from adjacent sectors

Qiagen, a major player in molecular diagnostics and life science sample technologies, announced on August 24, 2026, that Jonathan Pratt would succeed Thierry Bernard, effective September 1. Mr. Pratt previously led Filtration Group through to its sale to Parker-Hannifin in August, having previously served as President of Beckman Coulter Life Sciences alongside earlier leadership tenures at Waters and Pall. Mr. Bernard remained on to support the transition through year-end.

This case shows that an executive recruited from an adjacent sector—in this case analytical instrumentation and industrial filtration—can prove a compelling fit when the overarching mandate is operational and industrial. It also demonstrates a tight transition timeline: eight days between the public announcement and start date, with the outgoing leader staying on through late December. Such an aggressive schedule presupposes an alignment process thoroughly prepared well ahead of public disclosure.

What this requires across key leadership functions

Frequent missteps

Searching for a profile before codifying the mission.